Novartis Reports Phase 3 Results for Pelacarsen in Cardiovascular Disease
Novartis reports phase 3 Lp(a)HORIZON topline results for pelacarsen, an investigational ASO targeting Lp(a) production in patients with cardiovascular disease (CVD).
Myocardial Infarction | 05/09/2026 | By News Bureau
Tissue Dynamics and Galmed Pharmaceuticals partner to develop a human-centered cardiac fibrosis platform that will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair.
Myocardial Infarction | 07/05/2026 | By News Bureau | 112
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy